# China NMPA Drug Inspection - Hubei Qianjiang Pharmaceutical Co., Ltd. - Licorice (licorice tablets)

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/hubei-qianjiang-pharmaceutical-co-ltd/f53275ec-1ef8-4147-a00d-6c575ba46b15/
Source feed: China

> China NMPA drug inspection for Hubei Qianjiang Pharmaceutical Co., Ltd. published February 02, 2018. Drug: Licorice (licorice tablets). The State Administration for Market Regulation (NMPA) issued Announcement No. 23 of 2018 on February 2, 2018, detailing 

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Announcement No. 23 of 2018 from the State Administration of Traditional Chinese Medicine regarding 65 batches of substandard prepared slices of traditional Chinese medicine.
- Company Name: Hubei Qianjiang Pharmaceutical Co., Ltd.
- Publication Date: 2018-02-02
- Drug Name: Licorice (licorice tablets)
- Inspection Finding: The properties and content determination were substandard.
- Action Taken: Relevant provincial food and drug administration departments have taken control measures such as sealing and seizing goods, requiring enterprises to suspend sales and use, recall products, and rectify the situation. The State Food and Drug Administration has required that investigations be launched into illegal activities involving the production and sale of substandard drugs, and that the results be made public within three months, with a report on the relevant circumstances. If the drugs are indeed produced by the labeled manufacturer, they will be severely punished.
- Summary: The State Administration for Market Regulation (NMPA) issued Announcement No. 23 of 2018 on February 2, 2018, detailing significant quality issues with traditional Chinese medicine decoction pieces. Investigations conducted by the Beijing Institute for Drug Control identified 65 batches of non-compliant products from 61 enterprises.

Key findings revealed that 63 batches of licorice (licorice slices) and two batches of processed licorice root were substandard. Major violations included discrepancies in product appearance and failure to meet specified content determination standards, as outlined in the Pharmacopoeia of the People's Republic of China (2015 Edition). Notable companies involved in these violations included Jiangxi Zhangshu Tianqitang Traditional Chinese Medicine Decoction Pieces Co., Ltd., Beijing Guancheng Pharmaceutical Co., Ltd., and numerous others across various provinces.

In response, provincial food and drug administration departments were mandated to implement immediate control measures, such as product sealing, seizure, suspension of sales, recalls, and requiring enterprises to rectify issues. The State Food and Drug Administration instructed these departments to investigate illegal activities under Articles 73, 74, and 75 of the "Drug Administration Law of the People's Republic of China." Public disclosure of investigation results is required within three months, with severe penalties for confirmed violations. Enterprises also have a right to object to product authenticity, triggering further investigation.

Company: https://www.globalkeysolutions.net/companies/hubei-qianjiang-pharmaceutical-co-ltd/699fe3a9-41dd-437a-a8c7-d9fcf3559d46/